Hangzhou Qihan Biotech received IND clearance from the FDA for QT-019C, a universal allogeneic CAR-T therapy targeting autoimmune diseases. The off-the-shelf program is engineered from healthy donor leukapheresis products to stably express two CARs aimed at CD19 and BCMA, indicating a dual-target approach intended to expand activity across antigen profiles. The IND clearance sets up the next step toward clinical evaluation in patients, aligning with a broader industry shift toward scalable, off-the-shelf cell therapies for populations that would otherwise require individualized manufacturing. The reporting did not provide initial trial site or study design details beyond the clearance status. —